Just as the title of the episode indicates, Vaxart stock is on the rise after breaking out of the pennant pattern it has been in for some time now. As I mentioned in previous episodes, VXRT’s share price has been getting squeezed between ever narrowing highs and lows for a while and over the last couple days has broken past resistance and is testing a new support level. Bag holders like you and I know that this break above resistance will let the stock to continue to push higher as volume continues to move into the stock. Ready to talk Vaxart? Let’s go.

Welcome to Money Talkz, the gems I drop between the weekly Money Talk Sundayz podcast. I’m your investment bro Stevie Bee. Special shout out to all the new subs. I appreciate all of you. You know the business, run that like, share, and subscribe. If you’re a VXRT holder you definitely want to sub. This is a special edition of our Vaxart Watch.

Let’s get it.

As you can see on the chart, VXRT is making moves and breaking past its resistance level. You know how they say today’s price is not tomorrow’s price? Well yesterday’s resistance is today’s support for Vaxart. Things are trending favorably and now is definitely a time to grab up more shares of Vaxart before you get priced out.

The stock is trading above both the 50-day moving average (which is the green line there) and the 200-day moving average (which is the blue line there), indicating sentiment in the stock looks to be turning bullish. Each of these moving averages may hold as a possible area of support in the future. The Relative Strength Index (RSI) has pushed higher the past few days and now sits at 62 on the indicator. What this means is that buying pressure is strongly outweighing the selling pressure in the stock.

Ignore the FUD (fear, uncertainty, doubt)!!!! Focus on the facts!!! Vaxart is a winner! Moderna CEO has already come out saying that the current vaccines out are less effective against the new Omicron Covid variant. Vaccine resistance could lead to more sickness and hospitalizations and prolong the pandemic, and his comments triggered selling in growth-exposed assets like oil, stocks, and the Australian dollar.

We are anticipating even higher lows for VXRT. Over the next several days expect to see above average trading volume for Vaxart stock. Barring some crazy news expect the stock to remain above the moving averages. Stay bullish bros nation!

In press news, Vaxart, Inc. announced that the company’s vice president, Sean Tucker, will attend and speak at the World Vaccine & Immunotherapy Congress West Coast 2021, being held today. As of this recording it hasn’t happened yet, but I will let Bros Nation know how it goes.

It’s part of an award-winning series of conferences and exhibitions that’s steadily rising to become the world’s largest and most established vaccination events. Vaxart’s CSO will discuss the company’s research program for an oral candidate for the COVID-19 vaccine in the form of tablets. The medicine that needs to be swallowed against coronavirus is the only oral vaccine of its kind against COVID-19, which has immunological potential, which is confirmed. And this is the only vaccine that has been conducting Phase 2 clinical trials since October 2021.

If you haven’t done so, as a shareholder it is in your best interest to go to Vaxart.com and subscribe to their alerts.

It is the day after Thanksgiving and one of the first things to hit my alerts this morning was the news of a new Covid variant giving everyone pause. Rightfully so, the market’s response to this news was as expected so I had to check on my favorite biotech stock, VXRT. It was already up in premarket and closed the day up a little over 5%. in aftermarket it went up an additional 1% making me several hundred dollars on the day. If you tuned into the Winter is Coming episode on Vaxart you already know that this bump is indicative of what’s to come. In the last VXRT episode covering the squeeze pattern the stock is experiencing I said the stage is set for it to breakout. Are we on the verge of the next bull run? Let’s look at a couple of factors and you be the judge.

Welcome to Money Talk Sundayz. I’m your investment bro Stevie Bee with another installment of our Vaxart Watch. Run that like button. Subscribe and share if you’re feeling even more bullish on VXRT.

Here’s a bit of news I just found out and I haven’t heard or seen much chatter about it. We all know that Vaxart is conducting phase 2 trials of their covid vaccine tablet. What many of you may not have heard however is that the study will also be assessing the viability of the vaccine candidate as a “booster” for those who’ve received the injectable vaccine. Reports stated that the efficacy of the injectable vaccine wanes over time thus the need for a vaccine booster. The company’s Phase II trial is investigating its vaccine as a booster dose in people who have previously received an mRNA vaccine in their primary series. With the need for boosters comes more time for Vaxart to complete their phase 2 study.

The problem with the regular booster shots come from familiarity. Reports indicated adenovirus-vectored Covid-19 vaccines may face efficacy issues if they are used again as boosters because the immune system would be able to recognize and debilitate the vector.

Now obviously the convenience of the pill trumps many concerns and gives VXRT an advantage. Some are not needing a cold chain protocol, as well as doing away with needles, syringes, and vials. Also, as Vaxart chief scientific officer Sean Tucker points out, the vaccine has the additional potential benefit of sidestepping unwanted antivector responses as expected with other adenovirus-vectored vaccines. Vaxart uses the adenovirus type 5 (Ad5) as its vector. In addition, there is preclinical data showing its oral vaccine could also prevent SARS-CoV-2 transmission to unvaccinated individuals.

Just a little over a month ago crap outlets like the Motley Fool were claiming that it was too little too late for Vaxart but here we are with covid spikes around the globe and a new variant starting to make its rounds. Markets are reeling and countries are back to implementing travel bans just as the holiday season is kicking off. Vaxart is in a prime space to carve out its own niche in the vaccine market. Vaxart’s oral vaccine is much more straightforward to investigate in a clinical trial than ones that require a needle and syringe.

So how is the pill supposed to work you may be wondering. Vaxart’s Covid-19 vaccine tablet has a coating that allows it to survive the low pH in the stomach. Once it reaches the lower small intestine, its adenovirus vectors are released to infect epithelial cells. Once the genetic code is delivered, the host cell manufactures the SARS-CoV-2 spike antigen, as well as a double-stranded hairpin turn adjuvant. Vaxart’s vaccine draws a stronger response in the lower small intestine potentially due to specific immune system cells in this region, as well as local digestive enzymes assisting with the response.

From the covid pill to the flu vaccine Vaxart is making a name for itself as a revolutionary disruptor in the vaccine industry. Phase 2 clinical trials began in the third quarter for VXRT’s oral vaccine candidate with an expected completion date of spring 2022. Results from the Phase II human influenza challenge trial showed that those who were given VXA-A1.1 were better at providing protection against viral shedding compared to the injected inactivated influenza vaccine (IIV). All this while stock prices show a squeeze at the end of a pattern. Will Vaxart blow past resistance or crash through support? Let’s find out.

Welcome to Money Talk Sundayz. I’m your Investment Bro Stevie Bee. I hope you enjoyed my last VXRT episode. Run that like share and subscribe button. Let’s get to it.

A new study shows that there might be a way to protect against influenza infection without needing to stir up antibody response. Scientists from Stanford University investigated the effectiveness of an oral tablet flu vaccine called VXA-A1.1 by Vaxart, which uses cellular correlates of protection. Results from the Phase II human influenza challenge trial showed that those who were given VXA-A1.1 were better at providing protection against viral shedding compared to the injected inactivated influenza vaccine (IIV).

Those who received VXA-A1.1 were found with plasmablasts and hemagglutinin (HA+)-specific cells that contributed to protection from viral shedding after 90 days. This was not seen in those who got IIV or a placebo. On day 8, those who were given the oral drug demonstrated T cell expressing markers that suggested enhanced mucosal tissue homing.

Details of the VXA-A1.1 study are published in Cell Host and Microbe.

On the Covid front, the company began the first Phase II trial of their investigational COVID-19 oral tablet vaccine and dosed the first participants. The whole data set from this investigation is expected to be accessible in Q1 2022, according to Vaxart.

Published results by Duke University show that the company’s COVID-19 vaccine candidate reduced airborne transmission of the SARS-CoV-2 virus in a preclinical animal model. Vaxart also improved its research and manufacturing capacity, allowing it to move forward with the production of the vaccine candidate.

CEO Andrei Floroiu stated, “Vaxart made significant progress this quarter toward its goal of developing a next-generation oral tablet COVID-19 vaccine. We have started our United States Phase II trial and anticipate beginning international trials in the near future. This is an important milestone, as our candidate is the only oral COVID-19 vaccine to progress to Phase II trials in the U.S.”

Vaxart founder and Chief Scientific Officer Dr. Sean Tucker said The progress we made in our vaccine research this quarter was significant. We already learned from an earlier human influenza challenge study that our oral flu vaccine candidate inhibited the shedding of viral RNA better than injectable vaccines. In addition, our published hamster study showed that our vaccine candidate could reduce transmission of SARS-CoV-2, even when there is an infection breakthrough in a vaccinated subject. The implications are significant because existing injected vaccines do not always protect against viral shedding and transmission to other people.”

Vaxart Inc. stock is now 23.64% up from its year-to-date (YTD) trading value. VXRT Stock saw the intraday high of $7.29 and lowest of $6.77 per share.

Compared to the average trading volume of 3.53M shares, VXRT reached a trading volume of 5943937 in the most recent trading day, which is why market watchdogs consider the stock to be active.

With this latest performance, VXRT shares gained by 2.32% in over the last four-week period, additionally plugging by 5.37% over the last 6 months – not to mention a rise of 23.86% in the past year of trading.

Brief Summary:

Part 1: An open label, dose and age escalation phase to evaluate the safety and immunogenicity of VXA-CoV2-1.1-S with a repeat-dose vaccination schedule in healthy adults aged 18 - 75 years old that are either vaccine naive or have received prior vaccination with an mRNA (messenger ribonucleic acid) vaccine for the prevention of COVID-19.

Part 2: This phase will assess the efficacy of prophylactic VXA-CoV2-1.1-S against confirmed COVID-19 occurring from 7 days after second dose with a repeat-dose vaccination schedule in healthy adults compared to placebo. Safety and immunogenicity of VXA-CoV2-1.1-S will also be evaluated in this phase.

As the weather gets cooler and winter approaches, doctors are predicting a spike in COVID-19 cases and more hospitalizations which could put emergency departments at risk of being overwhelmed again.

California has begun positioning equipment and locking in contracts with temporary health care workers in preparation for another possible winter surge of coronavirus cases, Gov. Gavin Newsom said Wednesday.

VXRT’s earning reports are in and currently in phase 2 of their clinical trials for their Covid vaccine pill. Vaxart also rose 46.73% from its 52-week low and is up 20.67% year to date. While Covid numbers in the US are trending south, the rest of the world is still being ravaged. Do you buy, sell, or hold? Are we still bullish or are we now bearish? Let’s break it down in today’s episode of Money Talk Sundayz.

Thanks for tuning in to Money Talk Sundayz. I’m your investment Bro Stevie Bee. It’s been a few weeks since I last covered Vaxart so today we’re going to circle back and see what’s up with our favorite oral vaccine candidate stock. Hit that like button on your way in and let’s get started.

During the recent session, Vaxart Inc. (NASDAQ:VXRT)’s traded shares were 1.68 million, with the beta value of the company hitting 0.24. At the last check today, the stock’s price was $6.57, reflecting an intraday loss of -4.64% or -$0.32. The 52-week high for the VXRT share is $24.90, that puts it down -279.0 from that peak though still a striking 46.73% gain since the share price plummeted to a 52-week low of $3.50. The company’s market capitalization is $887.57M, and the average trade volume was 4.52 million shares over the past three months.

Vaxart Inc. (VXRT) is currently still a recommended Buy from analysts.

Vaxart Inc. (VXRT) registered a -4.64% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.64% in intraday trading to $6.57 this Thursday, 11/04/21, hitting a weekly high. The stock’s 5-day price performance is -0.14%, and it has moved by -2.96% in 30 days. Based on these gigs, the overall price performance for the year is 34.57%.

Per the CEO, VXRT’s oral vaccine candidate “is the only oral COVID-19 vaccine to progress to Phase II trials in the U.S.”

Vaxart recently brought online its own GMP manufacturing facility and is now producing vaccines at two GMP plants. This has allowed the Company to manufacture all of the COVID-19 vaccine oral tablets for the clinical trials started and planned to start this year, and to begin manufacturing vaccines for its upcoming norovirus Phase II trials.

Vaxart scaled up its research, quality and manufacturing capabilities, increasing its R&D employee headcount by more than 35% during the quarter.

Vaxart named Dr. James F. Cummings as its Chief Medical Officer. Dr. Cummings is a board-certified infectious disease physician with extensive experience in vaccine, drug and diagnostics development, and will help guide the Company’s development of its vaccines.

I hate, rather deplore the term, meme stock. The connotation behind it in my opinion throws shade on actual stocks. Before “meme stocks” the black sheep of trading was penny stocks. Haters swore there was no money in penny stocks. From experience I can say that is not true. Since the GameStop and AMC craze earlier this year the media has adopted the term meme stock and the term isn’t going away. Hard to fight the corporate machine. Since we can’t shirk the side eye of trading meme stocks, we can certainly take control of the narrative and win trading these stocks. Here’s how.

Welcome to Money Talk Sundayz. I’m your Investment Bro Stevie Bee. Hit that like button on your way in. Let’s talk meme stocks.

I want to share with you 9 things to keep in mind when playing the meme stock game. If you keep these in mind you will undoubtedly acquire and maintain a winning portfolio and keep the money flowing in.

#1 Nano Hands.

When I say nano hands, think Iron Man. His hands are capable of a variety of different actions from shooting lasers, jet propulsion, to coming off entirely. With meme stocks, your hands must be able to adapt with any situation that may arise. Therefore, forget the Diamond Hands nonsense and secure your profits whenever possible. You can sell and should sell when you feel comfortable. Do not, I repeat do not be pressured into holding onto a stock longer than you are comfortable with. If your gut is telling you, it’s time to cut it loose, CUT IT LOOSE! If you let the opinions and actions of others intimidate or enrage you, you are in the wrong game. Life is too short to be bothered with someone else’s opinions. Get your money and move on.

#2 Risk Tolerance.

In other words, only trade what you can afford to lose. If you find yourself in a position where you must choose between paying your rent/mortgage or car note or any other base necessity for living and trading meme stocks, you’re doing it all wrong. Take care of your business. Yes there is big money to be made and can be made in minutes as we’ve seen with Digital World Acquisition Corp (DWAC), Phunware (PHUN) and more but there is just as much money to be lost in a matter of minutes. When trading meme stocks you must honestly ask yourself, are you ok with losing this money.

#3 Meme Stock Volatility.

Meme stocks tend to be very volatile. So much so, at any given moment brokerages will halt trading on them as we’ve seen many times this year. Meme stocks swing faster than Brangelina at a swingers’ convention. Meme stocks move fast because they are heavily shorted and have an emotional component that hooks people in on a gut level. Meme stocks are also mostly owned by retail traders, so institutions have a smaller impact on movements.

#4 Accept the Meme Stock Consequences.

Acknowledge the fact that these are meme stocks and along with assessing your risk tolerance know you’re playing a dangerous game. Indeed, with high risk comes big rewards but it can also go the other way. Accept this fact that you are chasing big payouts quickly. That is the cold hard facts.

#5 Kill FOMO.

You missed out? Get over it. Don’t let FOMO drive your decisions. Perfect example is MARK or Remark Holdings. We talked about it last week. I also did a follow up to it. If you haven’t seen it check those two episodes out. MARK had a huge breakout in premarket last week Monday only to crash and burn. You need to accept when you’ve missed the boat. If you open your platform and that stock you were watching is up 300% from yesterday… let it go. By the time your jump in is in the books everyone else is taking their profits and running leaving you holding the bag. There will ALWAYS be another stock to trade.

Remark did as expected albeit after a quick and short lived run up in pre-market Monday morning. On Sunday during the podcast I reported that it was trading at 2.86. By the next morning it was well into the $6 range. The perfect time to play the put option, just as I mentioned during that episode. Let’s discuss what exactly happened with MARK.

Welcome to Money Talk Sundayz. Thanks for tuning in. Hit that like button on your way in the door and lets get started.

MARK was the big question for Monday. Sources from all walks of life were swearing by this stock as the one. But the more in premarket it rose the more inevitable the pullback or correction. And the pullback game was strong. Within 48 hours of the last episode Mark was down from over $6 to dipping below $2.

Some of you asked what happened. Why did it fall so much? The answer is pretty simple, human emotion. This stock like so many others is viewed as a meme stock. Investors in meme stocks for the most part are in it for the short term gains. A run up like what happened Monday morning is exactly what investors are looking for. They cash in quick and fast while like many of you who weren’t already invested catch on too late and buy up the shares they are selling overvalued thereby driving the price down.

One user told me that she bought in at $7 and was down $1100 by Monday afternoon. That is the game. Buy the news, sell the hype. Too many bought the hype aka the run up not realizing a swift fall was coming.

After being burned this way on a number of occasions, I offered up a suggestion on the podcast. I recommended a put option play banking that what happened was indeed going to happen. And it did! By close of business Monday my put option was up over 80%. I’m at work with multiple browser tabs open and one of the tabs was glued to the price of MARK as it fell. I eventually took my profits on that option play Wednesday being up 115%. It felt good being able to read the play… and with time and experience (losses) you will be able to do so too.

Funny thing is that Friday people were claiming that MARK was going to run up again on Friday claiming that the stock goes up on Fridays and ebbs on Mondays. Hype. Malarkey like Uncle Joe Biden says. I was skeptical of this but again I kept a close watch. It closed the day just over $2… about 2.04-05. So much for that run up lol. I will acknowledge that today it is trading at 2.11 so there was some gain but hardly enough to appease anyone who jumped in Monday morning above $5. 

Anyway, I’m done watching MARK. On to the next mark no pun intended. Well maybe a little intended. Interested in what I have my eyes set on for this week? Subscribe to the podcast and get your notifications first on what the next play is going to be.

Happy trading bros nation.

Remark Holdings Inc (MARK) stock is trading at $2.86, a gain of $0.69 on high volume. Remark Holdings Inc delivers an integrated suite of AI solutions that enable businesses and organizations to solve problems, reduce risk and deliver positive outcomes. The company's easy-to-install AI products are being rolled out in a range of applications within the retail, financial, public safety, and workplace arenas. The company also owns and operates digital media properties that deliver relevant content and e-commerce solutions. The group operates in one segment namely Technology & Data Intelligence segment which provides products and services to customers based upon the data collected and processed by its proprietary data intelligence software. So what is pushing MARK?

Welcome to Money Talk Sundayz. I’m your investment bro Stevie Bee. Go ahead and drop a like on the video. Let’s talk MARK.

Redditors are currently pushing MARK as the play for Monday. During after hours it is currently sitting at 2.86 a share. There is the real possibility of it going up further. What’s bananas though is that on Friday it opened at 0.91 and ran as high as 2.45 before closing at 2.17. As of this recording like I mentioned it is sitting at 2.86.

Here is the conundrum many who are not already invested in it are debating, does it have more room to grow or is it going to run out of steam and begin to dip? We saw the dip on Friday after a meteoric rise but again over the weekend we saw MARK surge once more. Those who believe it still has room to grow will jump in first thing Monday morning and hope that the wave continues throughout the day.

Skeptics will note the rise and like the mantra says, after every rise comes a fall.

What do we here at Money Talk Sundayz think? The market can go either way. We don’t know what’s going on behind closed doors. We are not aware of any back channel deals that are being made. We can only go off what is made publicly available to us and use that information to make an educated or emotional guess as to the direction this stock will take.

But what if you could have it both ways? What if you could bet on a rise and a fall and come out with a bag still?

Going back to the heart of this podcast, this is the play that I’m considering for MARK. Remember, the heart of this podcast is cataloging, documenting, sharing the plays the Investment Bros make on our marathon to 100K.

With that being said, this is what I’m looking to do.

First off, I don’t want to miss out on an opportunity to swing this stock for some profit so I’m putting in an order to purchase 100 shares. Considering its at 2.86 as of this broadcast, if it goes up $1-2 over the next 48 hours I’m a happy camper and sell off before the inevitable decline in share price of MARK. This in fact is my FOMO play.

Now let’s say it doesn’t go the way expected in the first play. Part 2 of this play is buying a put option with a November 19thexpiration (since that was the earliest available expiration offered when I tried). I buy one put option contract and if MARK craters from the over hype again and I’m a happy camper.

On a side note, lets say MARK goes up on Monday and continues its ride for a couple days next week and begins to fall the week after, I get to have my cake and eat it too. I make my profits off the short swing (if I sell in time) and then also get to cash in on the fall with the put option. I’m hedging my bets you can say. Regardless of whatever play I decide or you decide I can agree it’s too late to jump in on this stock for a long swing. I learned that the hard way with BTX. I bought in at 12. It ran up to 30. I didn’t sell. Now it’s sitting around 9. I’m sitting on a loss but a part of me is refusing to sell at a loss and want to recoup at the least what I put in.

Ocugen ticker symbol OCGN. You saw the posts. You heard the VXRT naysayers saying dump the stock and switch to OCGN. Ocugen this and OCGN that. Overvalued and overhyped, people in fear of losing out on a supposed bull run jumped on the OCGN bandwagon and got another lesson in buy the news, sell the hype. For more on OCGN stay tuned.

Welcome to Money Talk Sundayz. Hit the like button if you will on your way in the door. I’ll give you a few moments to get that out the way. While you’re there go ahead and subscribe and click that notification bell depending on the platform you’re tuning in. Let’s talk Ocugen.

Out the gate let me say I opened a put option on OCGN Wednesday and I’m currently up 28%. Why the put option despite all the hype that was swirling online about Ocugen? The signs. One thing I picked up along the way since I’ve begun this investing journey is how to differentiate news from hype.

Ocugen (NASDAQ:OCGN) is a small biotech firm. For years, it tried unsuccessfully to commercialize therapies for eye diseases. However, in 2020, it ended a Phase 3 trial on that front and pivoted to Covid-19. Its first effort in that regard, Covid-19 testing, totally failed to take off. The company is nothing if not persistent, however, and has now tried to get into the Covid-19 vaccine race. OCGN stock has been volatile based on these events.

To help with their lofty goals of wining their vaccine race, OCGN partnered with an Indian firm that had already developed a Covid-19 vaccine. Ocugen is supposed to obtain Food and Drug Administration (FDA) approval for the vaccine and launch it in North America. But the FDA didn’t give Ocugen the green light yet, and the company ended up getting sued by shareholders.

Similar to Vaxart, OCGN made lofty vaccine claims that they couldn’t back up. In March, the company said it intended to advance its vaccine’s development toward an emergency use authorization and ultimately a biologics license in the United States.

In June, however, it said that based on feedback from the U.S. Food and Drug Administration, it was no longer pursuing an emergency use application and was instead pursuing a biologics license application, which required an additional clinical trial and “will extend our timelines.”

The lawsuit charges the company knew its statements had been “materially false and misleading” and that it violated federal securities law.

But wait, there’s more.

Demand for a vaccine is starting to wane some. Ever since Merck announced it had developed a highly-effective therapeutic for treating Covid-19, vaccine stocks have been in freefall. Moderna (NASDAQ:MRNA), for example, has tumbled from $497 to just $310. There’s also been a good deal of uncertainty around the merits of booster shots of the vaccines. Add the two up, and traders have been quickly taking profits in the vaccine names. Let’s not forget that Ocugen’s product, however, hasn’t yet found commercial success in North America. Additionally, it’s gotten embroiled in scandal overseas.

OCGN is in hot water now that its partner on the vaccine, Bharat, has run into a legal logjam. It has been alleged that Bharat bribed Brazilian officials to win distribution for the vaccine in Brazil. This came after Brazil questioned the vaccine due to its rushed approval process.

Brazil’s organized crime investigation unit has already gotten involved, and some politicians have suggested this could be an impeachable offense against that country’s president. Regardless, it’s not a good look for a vaccine that is struggling to gain commercial traction to get embroiled in this sort of controversy. What vaccine-skeptical person who passed on vaccines from credible firms will rush to take this one instead?

Additionally Ocugen’s bad luck with the FDA continues with the regulatory agency pushing back on Ocugen’s attempts to launch the Covaxin vaccine in the U.S.

Vaxart is a game changer in the fight against Covid but now many are wondering…. Is it too late? The national infection rate is in a downward trend. The number of people dying from Covid is also going down. Merck is lobbying the FDA to approve their “therapeutic” Covid drug for use. It’s been at least a month since we’ve heard anything about new variants Lambda and Mu, both of which are said to be more infectious and lethal than the Delta variant. Is the Covid race really over for VXRT? Let’s find out.

Thanks for tuning Bros Nation. Hit that like button below and let’s get into it.

Multiple outlets are speculating that the race may be over for VXRT. It's clear the company missed out on vaccinating during the height of the pandemic. Moderna, Pfizer, and Johnson & Johnson shared that market.

Recently, former U.S. Food and Drug Administration (FDA) chief Dr. Scott Gottlieb told CNBC he expects the authorization of a coronavirus treatment pill and vaccines for kids to mark the transition from a pandemic into an endemic phase. Merck is requesting authorization of its treatment pill candidate which should come soon. And Pfizer has requested authorization of its vaccine in kids ages five through 11. So a post-pandemic world may be only months away.

All that being said, there are still a few key points that keep VXRT in the running.

A recent study in hamsters showed VXRT’s vaccine candidate reduces airborne transmission of coronavirus. This echo results from Vaxart's phase 2 study of its investigational flu vaccine in humans. The flu candidate cut viral shedding more than an injectable flu vaccine.

Additionally, healthcare facilities will find it easier to store a room-temperature-stable tablet than an injectable vaccine. (For example, the Moderna and Pfizer vaccines require cold temperatures.)

On top of that, like I’ve said in previous coverage of Vaxart, users prefer a pill over a needle and would gladly avoid the long lines and wait times at vaccination sites and healthcare facilities and cop the pill at the local pharmacy.

And while Merck’s pill is meant to treat the infection, Vaxart’s pill is meant to prevent infection in the first place.

Finally, globally a temperature-controlled vaccine doesn’t stand a chance against the pill in under-developed countries. The tablet will have a much broader reach into rural areas and will be far easier administered as opposed to the injectable counterpart.

That being said, it’s not over for VXRT. The market is still there. The demand is still there. My question now is, will it still be there next spring/summer when the first part of phase 2 trials is over? Do we hope for another variant to spread around the globe or do we start promoting Vaxart’s other tablets? Ladies and gentlemen, time is of the essence. Is Vaxart running a sprint or a marathon? What do you think? Is it over for VXRT? Let me know in the comments.

And that’s it. Thanks for listening. If you’ve made it this far, please subscribe to the podcast if you haven’t done so already. Share this information with your friends and fellow investors. If you have any questions, go ahead and send them my way. I’m still bullish on VXRT and will remain so. VXRT to the moon baby!